Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6901 to 6915 of 7680 results

  1. NGR-TNF for previously treated advanced malignant pleural mesothelioma [ID655]

    Discontinued [GID-TA10183]

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer [ID1168]

    Discontinued [GID-TA10208]

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued [GID-TA10330]

    Technology appraisal guidance
    Discontinued

  4. Pancreatic cancer - capecitabine [ID389]

    Discontinued [GID-TAG394]

    Technology appraisal guidance
    Discontinued

  5. Guadecitabine for untreated acute myeloid leukaemia [ID1411]

    Discontinued [GID-TA10325]

    Technology appraisal guidance
    Discontinued

  6. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued [GID-TA11238]

    Technology appraisal guidance
    Discontinued

  7. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued [GID-TA11239]

    Technology appraisal guidance
    Discontinued

  8. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued [GID-TA11240]

    Technology appraisal guidance
    Discontinued

  9. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued [GID-TA11241]

    Technology appraisal guidance
    Discontinued

  10. Selumetinib for treating differentiated thyroid cancer [ID1079]

    Discontinued [GID-TA10207]

    Technology appraisal guidance
    Discontinued

  11. Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]

    Discontinued [GID-TAG232]

    Technology appraisal guidance
    Discontinued

  12. Nivolumab for treating recurrent glioblastoma [ID998]

    Discontinued [GID-TA10126]

    Technology appraisal guidance
    Discontinued

  13. Liposomal vincristine for treating Philadelphia chromosome-negative acute lymphoblastic leukaemia after two therapies [ID954]

    Discontinued [GID-TA11181]

    Technology appraisal guidance
    Discontinued

  14. Masitinib for previously treated moderate Crohn's disease [ID1239]

    Discontinued [GID-TA11188]

    Technology appraisal guidance
    Discontinued

  15. Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]

    Discontinued [GID-TA11205]

    Technology appraisal guidance
    Discontinued